The TLR7 agonist induces tumor regression both by promoting CD4(+)T cells proliferation and by reversing T regulatory cell-mediated suppression via dendritic cells

Treg-induced immunosuppression is now recognized as a key element in enabling tumors to escape immune-mediated destruction. Although topical TLR7 therapies such as imiquimod have been proved successful in the treatment of dermatological malignancy and a number of conditions beyond the FDA-approved i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Wang, Chenchen, Zhou, Quan, Wang, Xiaofeng, Wu, Xiongyan, Chen, Xuehua, Li, Jianfang, Zhu, Zhenggang, Liu, Bingya, Su, Liping
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2014
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4359331/
https://ncbi.nlm.nih.gov/pubmed/25593198
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars